Structural basis for benzothiazinone-mediated killing of Mycobacterium tuberculosis

Science Translational Medicine

Volumn 4, Issue 150, 2012, Pages

  Neres, João ^a   Pojer, Florence ^a   Molteni, Elisabetta ^a,b   Chiarelli, Laurent R ^a,b   Dhar, Neeraj ^a   Boy Röttger, Stefanie ^a   Buroni, Silvia ^a,b   Fullam, Elizabeth ^a,e   Degiacomi, Giulia ^a,b,f   Lucarelli, Anna Paola ^b,g   Read, Randy J ^c   Zanoni, Giuseppe ^b   Edmondson, Dale E ^d   De Rossi, Edda ^a,b   Pasca, Maria Rosalia ^a,b   McKinney, John D ^a   Dyson, Paul J ^a   Riccardi, Giovanna ^a,b   Mattevi, Andrea ^b   Cole, Stewart T ^a   Binda, Claudia ^a,b   more..

^a EPFL   (Switzerland)

^b UNIVERSITY OF PAVIA   (Italy)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^f Physics and Informatics   (Slovakia)

^g ISTITUTO ITALIANO DI TECNOLOGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ARABINOSE; BENZOTHIAZINE DERIVATIVE; BTZ 043; CYSTEINE; DECAPRENYLPHOSPHORYL BETA DEXTRO RIBOFURANOSE 2' EPIMERASE; EPIMERASE; FLAVINE ADENINE NUCLEOTIDE; FLUORESCENT DYE; LYSINE; MENAQUINONE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ARTICLE; BACTERIAL CELL WALL; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; BIOCHEMISTRY; CARBOHYDRATE SYNTHESIS; CONTROLLED STUDY; COVALENT BOND; CRYSTAL STRUCTURE; DRUG POTENCY; DRUG RESEARCH; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVE SITE; ENZYME INACTIVATION; ENZYME INHIBITION; ENZYME LOCALIZATION; ENZYME MECHANISM; ENZYME STRUCTURE; EPIMERIZATION; MYCOBACTERIUM SMEGMATIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; SUICIDE SUBSTRATE; THREE DIMENSIONAL IMAGING; X RAY CRYSTALLOGRAPHY;

ANTITUBERCULAR AGENTS; BACTERIAL PROTEINS; CRYSTALLOGRAPHY, X-RAY; CYSTEINE; ENZYME INHIBITORS; FLAVIN-ADENINE DINUCLEOTIDE; FLAVOPROTEINS; FLUORESCENT DYES; KINETICS; LYSINE; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; MODELS, MOLECULAR; MUTAGENESIS, SITE-DIRECTED; MYCOBACTERIUM SMEGMATIS; MYCOBACTERIUM TUBERCULOSIS; OXIDATION-REDUCTION; OXIDOREDUCTASES; PROTEIN STRUCTURE, TERTIARY; PROTEIN TRANSPORT; SUBCELLULAR FRACTIONS; THIAZINES;

EID: 84865960733     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3004395     Document Type: Article

References (43)

1. A. A. Velayati, P. Farnia, M. R. Masjedi, T. A. Ibrahim, P. Tabarsi, R. Z. Haroun, H. O. Kuan, J. Ghanavi, M. Varahram, Totally drug-resistant tuberculosis strains: Evidence of adaptation at the cellular level. Eur. Respir. J. 34, 1202-1203 (2009).
2. M. Zignol, W. van Gemert, D. Falzon, C. Sismanidis, P. Glaziou, K. Floyd, M. Raviglione, Surveillance of anti-tuberculosis drug resistance in the world: An updated analysis, 2007-2010. Bull. World Health Organ. 90, 111-119D (2012).
3. S. T. Cole, G. Riccardi, New tuberculosis drugs on the horizon. Curr. Opin. Microbiol. 14, 570-576 (2011).
4. C. Lienhardt, M. Raviglione, M. Spigelman, R. Hafner, E. Jaramillo, M. Hoelscher, A. Zumla, J. Gheuens, New drugs for the treatment of tuberculosis: Needs, challenges, promise, and prospects for the future. J. Infect. Dis. 205 (Suppl. 2), S241-S249 (2012).
5. V. Makarov, G. Manina, K. Mikusova, U. Möllmann, O. Ryabova, B. Saint-Joanis, N. Dhar, M. R. Pasca, S. Buroni, A. P. Lucarelli, A. Milano, E. De Rossi, M. Belanova, A. Bobovska, P. Dianiskova, J. Kordulakova, C. Sala, E. Fullam, P. Schneider, J. D. McKinney, P. Brodin, T. Christophe, S. Waddell, P. Butcher, J. Albrethsen, I. Rosenkrands, R. Brosch, V. Nandi, S. Bharath, S. Gaonkar, R. K. Shandil, V. Balasubramanian, T. Balganesh, S. Tyagi, J. Grosset, G. Riccardi, S. T. Cole, Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis. Science 324, 801-804 (2009).
6. P. K. Crellin, R. Brammananth, R. L. Coppel, Decaprenylphosphoryl-β- D-ribose 2′-epimerase, the target of benzothiazinones and dinitrobenzamides, is an essential enzyme in Mycobacterium smegmatis. PLoS One 6, e16869 (2011).
7. C. M. Sassetti, E. J. Rubin, Genetic requirements for mycobacterial survival during infection. Proc. Natl. Acad. Sci. U.S.A. 100, 12989-12994 (2003).
8. K. Mikusová, H. Huang, T. Yagi, M. Holsters, D. Vereecke, W. D'Haeze, M. S. Scherman, P. J. Brennan, M. R. McNeil, D. C. Crick, Decaprenylphosphoryl arabinofuranose, the donor of the D-arabinofuranosyl residues of mycobacterial arabinan, is formed via a two-step epimerization of decaprenylphosphoryl ribose. J. Bacteriol. 187, 8020-8025 (2005).
9. B. A. Wolucka, Biosynthesis of D-arabinose in mycobacteria - A novel bacterial pathway with implications for antimycobacterial therapy. FEBS J. 275, 2691-2711 (2008).
10. M. R. Pasca, G. Degiacomi, A. L. Ribeiro, F. Zara, P. De Mori, B. Heym, M. Mirrione, R. Brerra, L. Pagani, L. Pucillo, P. Troupioti, V. Makarov, S. T. Cole, G. Riccardi, Clinical isolates of Mycobacterium tuberculosis in four European hospitals are uniformly susceptible to benzothiazinones. Antimicrob. Agents Chemother. 54, 1616-1618 (2010).
11. T. Christophe, M. Jackson, H. K. Jeon, D. Fenistein, M. Contreras-Dominguez, J. Kim, A. Genovesio, J. P. Carralot, F. Ewann, E. H. Kim, S. Y. Lee, S. Kang, M. J. Seo, E. J. Park, H. Skovierová, H. Pham, G. Riccardi, J. Y. Nam, L. Marsollier, M. Kempf, M. L. Joly-Guillou, T. Oh, W. K. Shin, Z. No, U. Nehrbass, R. Brosch, S. T. Cole, P. Brodin, High content screening identifies decaprenyl-phosphoribose 2′ epimerase as a target for intracellular antimycobacterial inhibitors. PLoS Pathog. 5, e1000645 (2009).
12. S. Magnet, R. C. Hartkoorn, R. Székely, J. Pató, J. A. Triccas, P. Schneider, C. Szántai-Kis, L. Orfi, M. Chambon, D. Banfi, M. Bueno, G. Turcatti, G. Kéri, S. T. Cole, Leads for antitubercular compounds from kinase inhibitor library screens. Tuberculosis 90, 354-360 (2010).
13. C. Trefzer, H. Škovierová, S. Buroni, A. Bobovská, S. Nenci, E. Molteni, F. Pojer, M. R. Pasca, V. Makarov, S. T. Cole, G. Riccardi, K. Mikušová, K. Johnsson, Benzothiazinones are suicide inhibitors of mycobacterial decaprenylphosphoryl-β-D-ribofuranose 2′-oxidase DprE1. J. Am. Chem. Soc. 134, 912-915 (2012).
14. A. L. Ribeiro, G. Degiacomi, F. Ewann, S. Buroni, M. L. Incandela, L. R. Chiarelli, G. Mori, J. Kim, M. Contreras-Dominguez, Y. S. Park, S. J. Han, P. Brodin, G. Valentini, M. Rizzi, G. Riccardi, M. R. Pasca, Analogous mechanisms of resistance to benzothiazinones and dinitrobenzamides in Mycobacterium smegmatis. PLoS One 6, e26675 (2011).
15. G. Manina, M. R. Pasca, S. Buroni, E. De Rossi, G. Riccardi, Decaprenylphosphoryl-β-D-ribose 2′-epimerase from Mycobacterium tuberculosis is a magic drug target. Curr. Med. Chem. 17, 3099-3108 (2010).
16. C. Trefzer, M. Rengifo-Gonzalez, M. J. Hinner, P. Schneider, V. Makarov, S. T. Cole, K. Johnsson, Benzothiazinones: Prodrugs that covalently modify the decaprenylphosphoryl-β-D-ribose 2′-epimerase DprE1 of Mycobacterium tuberculosis. J. Am. Chem. Soc. 132, 13663-13665 (2010).
17. M. W. Fraaije, W. J. H. Van Berkel, J. A. E. Benen, J. Visser, A. Mattevi, A novel oxidoreductase family sharing a conserved FAD-binding domain. Trends Biochem. Sci. 23, 206-207 (1998).
18. E. Malito, A. Coda, K. D. Bilyeu, M. W. Fraaije, A. Mattevi, Structures of Michaelis and product complexes of plant cytokinin dehydrogenase: Implications for flavoenzyme catalysis. J. Mol. Biol. 341, 1237-1249 (2004).
19. F. Forneris, D. P. H. M. Heuts, M. Delvecchio, S. Rovida, M. W. Fraaije, A. Mattevi, Structural analysis of the catalytic mechanism and stereoselectivity in Streptomyces coelicolor alditol oxidase. Biochemistry 47, 978-985 (2008).
20. K. Arnold, L. Bordoli, J. Kopp, T. Schwede, The SWISS-MODEL workspace: A web-based environment for protein structure homology modelling. Bioinformatics 22, 195-201 (2006).
21. N. Guex, M. C. Peitsch, SWISS-MODEL and the Swiss-PdbViewer: An environment for comparative protein modeling. Electrophoresis 18, 2714-2723 (1997).
22. T. Schwede, J. Kopp, N. Guex, M. C. Peitsch, SWISS-MODEL: An automated protein homology-modeling server. Nucleic Acids Res. 31, 3381-3385 (2003).
23. T. A. Smith, J. H. Baker, Progress in polyamine research, in Novel Biochemical, Pharmacological and Clinical Aspects, V. Zappia, E. P. Kennedy, B. I. Nilsson, P. Galletti, Eds. (Plenum Press, New York, 1988), pp. 573-589.
24. D. J. VanderJagt, P. J. Garry, W. C. Hunt, Ascorbate in plasma as measured by liquid chromatography and by dichlorophenolindophenol colorimetry. Clin. Chem. 32, 1004-1006 (1986).
25. D. S. Coffey, L. Hellerma, The interaction of 2,6-dichloroindophenol and protein sulfhydryl groups. Biochim. Biophys. Acta 100, 98-103 (1965).
26. K. Tahlan, H. I. Boshoff, New cell wall biosynthesis inhibitors under active development for tuberculosis. Drugs Future 34, 739-748 (2009).
27. N. R. Thanky, D. B. Young, B. D. Robertson, Unusual features of the cell cycle in mycobacteria: Polar-restricted growth and the snapping-model of cell division. Tuberculosis 87, 231-236 (2007).
28. D. A. Rozwarski, G. A. Grant, D. H. R. Barton, W. R. Jacobs Jr., J. C. Sacchettini, Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis. Science 279, 98-102 (1998).
29. A. Liav, E. Swiezewska, E. Ciepichal, P. J. Brennan, Stereoselectivity in the synthesis of polyprenylphosphoryl b-D-ribofuranoses. Tetrahedron Lett. 47, 8781-8783 (2006).
30. A. G. W. Leslie, Integration of macromolecular diffraction data. Acta Crystallogr. D Biol. Crystallogr. 55, 1696-1702 (1999).
31. M. D. Winn, C. C. Ballard, K. D. Cowtan, E. J. Dodson, P. Emsley, P. R. Evans, R. M. Keegan, E. B. Krissinel, A. G. W. Leslie, A. McCoy, S. J. McNicholas, G. N. Murshudov, N. S. Pannu, E. A. Potterton, H. R. Powell, R. J. Read, A. Vagin, K. S.Wilson, Overview of the CCP4 suite and current developments. Acta Crystallogr. D Biol. Crystallogr. 67, 235-242 (2011).
32. A. J. McCoy, Solving structures of protein complexes by molecular replacement with Phaser. Acta Crystallogr. D Biol. Crystallogr. 63, 32-41 (2007).
33. J. Söding, A. Biegert, A. N. Lupas, The HHpred interactive server for protein homology detection and structure prediction. Nucleic Acids Res. 33, W244-W248 (2005).
34. G. Bunkóczi, R. J. Read, Improvement of molecular-replacement models with Sculptor. Acta Crystallogr. D Biol. Crystallogr. 67, 303-312 (2011).
35. T. C. Terwilliger, F. Dimaio, R. J. Read, D. Baker, G. Bunkóczi, P. D. Adams, R. W. Grosse-Kunstleve, P. V. Afonine, N. Echols, phenix.mr-rosetta: Molecular replacement and model rebuilding with Phenix and Rosetta. J. Struct. Funct. Genomics 13, 81-90 (2012).
36. P. Emsley, K. Cowtan, Coot: Model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60, 2126-2132 (2004).
37. G. N. Murshudov, A. A. Vagin, E. J. Dodson, Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. D Biol. Crystallogr. 53, 240-255 (1997).
38. G. J. Kleywegt, T. A. Jones, Detection, delineation, measurement and display of cavities in macromolecular structures. Acta Crystallogr. D Biol. Crystallogr. 50, 178-185 (1994).
39. S. McNicholas, E. Potterton, K. S. Wilson, M. E. M. Noble, Presenting your structures: The CCP4mg molecular-graphics software. Acta Crystallogr. D Biol. Crystallogr. 67, 386-394 (2011).
40. W. Kabsch, XDS. Acta Crystallogr. D Biol. Crystallogr. 66, 125-132 (2010).
41. R. A. Copeland, Enzymes: A Practical Introduction to Structure, Mechanism and Data Analysis (John Wiley & Sons Inc., New York, ed. 2, 2000).
42. G. Jones, P. Willett, R. C. Glen, Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation. J. Mol. Biol. 245, 43-53 (1995).
43. V. A. Makarov, Application: WO2011132070 (2011).